Quarterly ResultAug 5, 2026, 07:07 AM
Lifecore Biomedical Q2 Revenue $34.2M; Net Loss $6.2M
AI Summary
Lifecore Biomedical reported Q2 2026 revenues of $34.2 million, a 6.2% decrease year-over-year, and a net loss of $6.2 million, or $0.19 per diluted share. Adjusted EBITDA for the quarter was $8.6 million, down from $9.1 million in the comparable prior year quarter. Despite the financial declines, the company reaffirmed its full-year 2026 revenue guidance of $120 million to $125 million and Adjusted EBITDA guidance of $20.5 million to $25 million, citing multiple new business wins and ongoing cost reduction efforts.
Key Highlights
- Q2 2026 revenue decreased 6.2% to $34.2 million compared to prior year.
- Q2 2026 net loss widened to $6.2 million, or $0.19 per diluted share.
- Q2 2026 Adjusted EBITDA was $8.6 million, a decrease of $0.5 million.
- Reaffirmed 2026 revenue guidance of $120 million to $125 million.
- Reaffirmed 2026 Adjusted EBITDA guidance of $20.5 million to $25 million.
- Signed 6 new programs in Q2 2026, including 2 commercial stage programs.
- Ended Q2 2026 with $38.8 million in liquidity, including $17.2 million cash.
Price Impact
More from LFCR